08:00 AM EDT, 05/19/2025 (MT Newswires) -- Ionis Pharmaceuticals ( IONS ) said Monday that a study of olezarsen in people with moderate hypertriglyceridemia with or at risk for atherosclerotic cardiovascular disease met its primary endpoint, as well as all key secondary endpoints.

Results showed a "statistically significant" placebo-adjusted 61% and 58% reduction in triglyceride levels at six months with the 80-milligram and 50 mg monthly doses, respectively, the company said.

Olezarsen also showed a favorable safety and tolerability profile, according to Ionis.

The company expects data from the pivotal phase 3 CORE and CORE2 studies assessing olezarsen to treat severe hypertriglyceridemia in Q3.

Triglycerides are a kind of fat the body uses as a source of energy.

Ionis shares were up 1% in recent premarket activity.